PABLO
RYAN MÚRUA
Profesor asociado de Ciencias de la Salud
Hospital Clínico San Carlos de Madrid
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital Clínico San Carlos de Madrid (22)
2023
-
Patterns of Sexualized Drug Use among Gay, Bisexual, and Other Men Who Have Sex with Men Living with HIV: Insights from a Comprehensive Study—The U-SEX-2 GESIDA 9416 Study
Journal of Clinical Medicine, Vol. 12, Núm. 23
-
Recently acquired hepatitis C: Epidemiological characteristics and treatment response in a large cohort of MSM living with HIV in Madrid
Enfermedades Infecciosas y Microbiologia Clinica
-
Tenofovir Disoproxil Fumarate/Emtricitabine and Baricitinib for Patients at High Risk of Severe Coronavirus Disease 2019: The PANCOVID Randomized Clinical Trial
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, Vol. 76, Núm. 3, pp. e116-e125
2022
-
Different profiles among older adults with HIV according to their chronological age and the year of HIV diagnosis: The FUNCFRAIL cohort study (GeSIDA 9817)
PloS one, Vol. 17, Núm. 3, pp. e0266191
-
Pregnancy Outcomes Among Perinatally HIV-Infected Women in Spain
Journal of acquired immune deficiency syndromes (1999), Vol. 91, Núm. 4, pp. 373-380
2020
-
Health care issues affecting transgender people living with HIV: an opportunity for improvement
International Journal of STD and AIDS, Vol. 31, Núm. 9, pp. 859-865
-
Virological outcome among HIV infected patients transferred from pediatric care to adult units in Madrid, Spain (1997–2017)
Scientific Reports, Vol. 10, Núm. 1
2019
-
Candidemia in solid organ transplant recipients in Spain: Epidemiological trends and determinants of outcome
Transplant Infectious Disease, Vol. 21, Núm. 6
-
Drug-related and psychopathological symptoms in HIV-positive men who have sex with men who inject drugs during sex (slamsex): Data from the U-SEX GESIda 9416 study
PLoS ONE, Vol. 14, Núm. 12
-
HIV coinfection predicts failure of ledipasvir/sofosbuvir in treatment-naïve noncirrhotic patients with HCV genotype
Open Forum Infectious Diseases, Vol. 6, Núm. 5
2018
-
All-oral direct-acting antiviral therapy against hepatitis C virus (HCV) in human immunodeficiency virus/HCV–coinfected subjects in real-world practice: Madrid coinfection registry findings
Hepatology, Vol. 68, Núm. 1, pp. 32-47
-
Increased indoleamine-2,3-dioxygenase activity is associated with poor clinical outcome in adults hospitalized with influenza in the INSIGHT FLU003Plus study
Open Forum Infectious Diseases, Vol. 5, Núm. 1
-
Sexualized Drug Use (Chemsex) Is Associated with High-Risk Sexual Behaviors and Sexually Transmitted Infections in HIV-Positive Men Who Have Sex with Men: Data from the U-SEX GESIDA 9416 Study
AIDS Patient Care and STDs, Vol. 32, Núm. 3, pp. 112-118
2017
-
Epidemiology and prognosis of candidaemia in elderly patients
Mycoses, Vol. 60, Núm. 12, pp. 808-817
-
Evaluation of the possible influence of trailing and paradoxical effects on the clinical outcome of patients with candidemia
Clinical Microbiology and Infection, Vol. 23, Núm. 1, pp. 49.e1-49.e8
-
Impact of fluconazole susceptibility on the outcome of patients with candidaemia: data from a population-based surveillance
Clinical Microbiology and Infection, Vol. 23, Núm. 9, pp. 672.e1-672.e11
2016
-
Empirical and targeted therapy of candidemia with fluconazole versus echinocandins: a propensity score–derived analysis of a population-based, multicentre prospective cohort
Clinical Microbiology and Infection, Vol. 22, Núm. 8, pp. 733.e1-733.e8
2015
-
A simple prediction score for estimating the risk of candidaemia caused by fluconazole non-susceptible strains
Clinical Microbiology and Infection, Vol. 21, Núm. 7, pp. 684.e1-684.e9
-
Candida tropicalis bloodstream infection: Incidence, risk factors and outcome in a population-based surveillance
Journal of Infection, Vol. 71, Núm. 3, pp. 385-394
-
Dual treatment with lopinavir-ritonavir plus lamivudine versus triple treatment with lopinavir-ritonavir plus lamivudine or emtricitabine and a second nucleos(t)ide reverse transcriptase inhibitor for maintenance of HIV-1 viral suppression (OLE): A randomised, open-label, non-inferiority trial
The Lancet Infectious Diseases, Vol. 15, Núm. 7, pp. 785-792